Here is a curious result from a small Japanese trial: people with mild cognitive impairment (MCI) took 500 mg a day of a dipeptide found in chicken breast and fish. After 12 weeks, their memory-related test scores rose by about two points. The placebo group did not move at all.
The compound is anserine. It is not a household name in the supplement aisle, but it has been quietly building a research record. This 2021 randomized controlled trial in Aging is one of the more interesting entries, and also one that deserves careful reading.
What Is Anserine?
Anserine (beta-alanyl-3-methyl-L-histidine) is a dipeptide, meaning two amino acids joined together. It is a close chemical relative of carnosine, a better-known compound studied for antioxidant and anti-glycation activity. Both belong to a family called histidine-containing dipeptides.
Anserine is abundant in the muscle of birds and fish. Chicken breast is a classic source, and tuna and other fish are rich in it too. That is why it shows up in searches like "chicken breast peptide brain." Anserine is also sold as a standalone supplement, often derived from chicken or fish extracts, and frequently blended with carnosine.
The Trial: Who, What, and How Long
The study, led by Masuoka and colleagues with senior author Tatsuhiro Hisatsune, was a randomized, placebo-controlled human trial in Japan.
- Screened: 58 elderly volunteers
- Randomized: 36 people with MCI, assigned to 500 mg anserine per day or placebo
- Duration: 12 weeks
- Analyzed: 30 completers, 15 in each arm
- Outcome: Mini-Mental State Examination (MMSE) at baseline and after the intervention
The Numbers
The anserine group improved on the MMSE by an average of +1.9 points (SD 2.0). The placebo group changed by 0 points (SD 2.8). The between-group difference was statistically significant at p = 0.036.
The researchers also adjusted for each person's daily dietary intake of anserine, since people eating more chicken and fish would be getting extra from food. After that correction the result strengthened to p = 0.0176.
The MMSE is scored out of 30, so a 1.9-point gain is modest. Still, in a group where the usual expectation is stability or slow decline, a flat placebo arm against a rising treatment arm is what researchers hope to see in an early signal.
The Mechanism in Plain English
Alzheimer's disease is increasingly viewed as having an inflammatory component, not only a plaque-and-tangle problem. The authors focus on one particular chain of events:
- Immune cells called neutrophils release an enzyme, myeloperoxidase (MPO).
- MPO produces hypochlorous acid (HClO), the same reactive chemical family as household bleach, which is useful for killing germs.
- In the brain, excess HClO can damage tissue and fuel neuroinflammation, which has been implicated in Alzheimer's progression.
The proposed role of anserine is as an HClO scavenger. It mops up the reactive molecule, which would dampen the MPO-driven inflammatory cascade. In effect, the idea is to turn down a slow chemical fire in the brain before it does more harm.
To be clear, this study measured cognition, not inflammatory markers in the brain. The mechanism is a plausible explanation the authors propose, not something this trial directly proved.
How It Fits With Carnosine and the Wider Evidence
Anserine does not stand alone. Earlier Japanese trials used anserine/carnosine blends, typically at a 4:1 ratio and around 1 g per day, and reported benefits in some aspects of memory and brain blood flow in older adults.
More recently, a 2024 meta-analysis in Nutrition Reviews pooled studies of histidine-containing dipeptides and found improvements in delayed recall, the ability to remember something after a pause. That is a meaningful finding, since delayed recall is among the earliest abilities to slip in Alzheimer's-type decline.
The trial discussed here adds something slightly different: a result for anserine on its own, at a lower dose, in people who already had MCI.
Practical Takeaways
Dose. The trial used 500 mg per day of anserine. Blend products used in earlier research delivered roughly 1 g per day of combined dipeptides.
Food sources. Chicken breast and fish such as tuna are natural sources. The researchers adjusted for dietary intake because food contributes to total exposure. Getting meaningful amounts from diet alone can be hard to estimate, which is partly why supplements exist.
Product types. You will see two main forms: standalone anserine and anserine/carnosine blends. The evidence base for the blends and for anserine alone is separate, so check labels for actual milligrams per serving.
Who it might interest. Older adults with subjective memory concerns or diagnosed MCI, ideally in conversation with a physician. It is not a treatment for dementia, and it is not a substitute for medical evaluation, exercise, sleep, blood pressure control, or other well-supported habits.
Honest Limitations
This is promising, but it is early evidence, and the caveats are significant:
- Small sample. Only 30 people were analyzed, 15 per group. Small trials can overstate effects.
- Short duration. Twelve weeks says nothing about long-term effects or whether benefits persist.
- One test. The primary outcome was the MMSE, a fairly blunt screening tool that can fluctuate with practice and mood.
- Single country. All participants were in Japan, with dietary patterns that may differ from other populations.
- Dropouts. Of 36 randomized, 30 were analyzed, which can influence results.
- Borderline significance. A p-value of 0.036 is below the usual threshold, but not by a wide margin, and replication matters.
None of this means anserine does not work. It means the finding needs larger, longer, multi-site trials with broader cognitive batteries and biomarker measurements to confirm both the benefit and the HClO mechanism.
Bottom Line
Anserine is a food-derived dipeptide with a plausible anti-inflammatory rationale and a small but encouraging human trial behind it. A 500 mg daily dose was associated with a roughly 2-point MMSE gain over 12 weeks while placebo stayed flat. Combined with earlier blend studies and a 2024 meta-analysis pointing to better delayed recall, it is one of the more credible emerging supplement candidates for cognitive health. It remains a candidate, not a proven therapy. If you are considering it, talk to your doctor, especially if you have memory concerns that warrant proper assessment.
